Commentaries
Commentary: Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study
A research group led by Catherine Smith from St John’s Institute of Dermatology described humoral and cellular immunity.
Tuesday, January 25, 2022
